Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 201

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 5
Chunk 201
---
Market Information 

Our common stock began trading on the Nasdaq Global Select Market on February 5, 2021, and trades under the symbol “BOLT”.  Effective January 6, 2025, our common stock was transferred to and now trades on the Nasdaq Capital Market under the same symbol. Prior to February 5, 2021, there was no public market for our common stock.

Holders of Common Stock 

On March 19, 2025, there were approximately 13 holders of record of our common stock. Certain shares are held in “street” name and accordingly, the number of beneficial owners of such shares is not known or included in the foregoing number. 

Dividend Policy 

We have never declared or paid any dividends on our common stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant. 

Stock Price Performance Graph 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide this information. 

Securities Authorized for Issuance under Equity Compensation Plans 

Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K. 

Recent Repurchases of Equity Securities. 

None. 

Recent Sales of Unregistered Securities. 

None.